The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
复制标题
长链非编码 RNA CCAT2 在卵巢癌中上调并与不良预后相关
DOI：
10.1186/s13000-016-0499-x
复制
发表时间：
2016-06-10
影响因子：
2.6
通讯作者：
Zhu Y
中科院分区：
文献类型：
--
作者：
Huang S;Qing C;Huang Z;Zhu Y
卵巢癌是一种预后不良的恶性肿瘤。越来越多的证据表明，长链非编码rna （long non-coding RNAs, lncRNAs）是癌症生物学中新兴的调控因子，可作为癌症诊断、预后和靶向治疗的潜在生物标志物。lncRNA CCAT2（结肠癌相关转录本2）最近被证明与几种癌症有关；然而，它在卵巢癌中的作用尚不清楚。实时荧光定量PCR检测lncRNA CCAT2在卵巢癌组织、癌旁正常组织和细胞系中的表达水平。然后，评估CCAT2表达水平与临床病理特征和预后的关系。此外，通过体外sirna诱导CCAT2沉默，进一步确定CCAT2在肿瘤进展和侵袭中的功能。lncRNA CCAT2在卵巢癌组织和细胞系中的表达水平明显高于邻近的非肿瘤组织和正常卵巢上皮细胞。有趣的是，在卵巢癌患者中，较高的CCAT2表达水平与较短的总生存期（P = 0.006）和无病生存期（P = 0.001）相关。CCAT2表达与FIGO分期（P = 0.002）、肿瘤分级（P = 0.006）、远处转移（P < 0.001）呈正相关。此外，CCAT2敲低在卵巢癌细胞中显著抑制细胞增殖、迁移和侵袭。lncRNA CCAT2是参与卵巢癌进展的新因子，是卵巢癌患者潜在的预后生物标志物和治疗靶点。
Ovarian cancer is a malignant tumor with a poor prognosis. Accumulating evidence demonstrates that long non-coding RNAs (lncRNAs) are emerging regulators in cancer biology, and can be used as potential biomarkers for cancer diagnosis, prognosis and targeted therapy. The lncRNA CCAT2 (colon cancer associated transcript 2) was recently shown to be involved in several cancers; however, its role in ovarian cancer remains unknown. Expression levels of the lncRNA CCAT2 in ovarian cancer tissues, adjacent normal tissues, and cell lines were assessed by quantitative real-time PCR. Then, the associations of CCAT2 expression levels with clinicopathological features and prognosis were evaluated. In addition, CCAT2 functions in tumor progression and invasion were further determined by siRNA-induced CCAT2 silencing in vitro. Expression levels of the lncRNA CCAT2 in ovarian cancer tissues and cell lines were significantly higher compared with values obtained for adjacent non-tumor tissues and normal ovarian epithelial cells. Interestingly, higher CCAT2 expression levels were associated with a shorter overall survival (P = 0.006) and disease-free survival (P = 0.001) in ovarian cancer patients. In addition, CCAT2 expression was positively correlated with FIGO stage (P = 0.002), tumor grade (P = 0.006) and distant metastasis (P < 0.001). Moreover, CCAT2 knockdown in ovarian cancer cells markedly suppressed cell proliferation, migration, and invasion. The lncRNA CCAT2 is a novel factor involved in ovarian cancer progression, and constitutes a potential prognostic biomarker and therapeutic target for patients with ovarian cancer.